Mass Balance Study of TQB3616
Clinical Study on Material Balance of [14C]TQB3616 in Healthy Chinese Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Liyan Miao, Master of Medicine
- Phone Number: 13862592687
- Email: miaolysuzhou@163.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- The First Affiliated Hospital of Soochow University
-
Contact:
- Liyan Miao, Master of Medicine
- Phone Number: 13862592687
- Email: miaolysuzhou@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adult male;
- Age: 18-45 years old (inclusive);
- The body mass index (BMI) is between 19-26 kg/m2 (inclusive), and the subject's body weight shall be not less than 50 kg (inclusive);
- Voluntarily sign the informed consent form;
- The subjects are able to communicate well with the investigators and complete the study according to the protocol.
Exclusion Criteria:
- Abnormal and clinically significant results in comprehensive physical examination, vital signs, digital examination of the anus, laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function, fecal routine+occult blood, thyroid function, etc.), 12-lead electrocardiogram, chest X-ray (Posterior-anterior), abdominal ultrasound (liver, gallbladder, pancreas, spleen, kidney), ect.;
- Abnormal and clinically significant results in ophthalmic examinations (slit lamp, intraocular pressure, and fundus photography);
- Any one of hepatitis B surface antigen, hepatitis B e antigen, hepatitis C antibody, HIV antibody and syphilis antibody is positive;
- Within 30 days before the screening period, those who have used any drugs that inhibit or induce liver drug metabolism (such as CYP3A4 inducers like carbamazepine, dexamethasone, rifampicin, phenytoin, phenobarbital, rifabutin, rifapentine, hypericum perforatum, etc.; CYP3A4 inhibitors like itraconazole, ketoconazole, clarithromycin, voriconazole, telithromycin, saquinavir, lopinavir, ritonavir, etc.);
- Within 14 days prior to the screening period, have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health products;
- Those who have participated in any drug clinical trial and received any investigational drug within 3 months prior to the screening period;
- Have a history of any clinically serious illness or condition that the investigator believes may affect the test results, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, or blood, immune, mental, and metabolic diseases;
- Having undergone major surgery or incomplete healing of the surgical incision within 6 months prior to the screening period; Major surgeries include, but are not limited to, any surgeries with significant bleeding risks, prolonged general anesthesia, or open biopsies or obvious traumatic injuries.
- Individuals with allergic constitution, including those with a history of drug allergy, known to be allergic to TQB3616 or similar drugs or its excipients, be allergic to any food ingredient or has special dietary requirements, and cannot follow a unified diet;
- Hemorrhoids or perianal diseases with regular/ongoing bloody stools; The presence of gastrointestinal dysfunction such as irritable bowel syndrome and inflammatory bowel disease that may affect drug absorption, distribution, metabolism, and excretion, as determined by investigators;
- Habitual constipation or diarrhea;
- Excessive drinking or frequent drinking within 6 months prior to the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit=360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine); Or during the screening period, the alcohol breath test result is ≥ 20 mg/dL;
- Those who smoke more than 5 cigarettes per day or habitually use nicotine containing products within 3 months prior to the screening period, and are unable to quit during the trial period;
- Abuse of drugs or use of soft drugs (such as marijuana) within 3 months prior to the screening period, or use of hard drugs (such as cocaine, amphetamines, phencyclidine, etc.) within 1 year prior to the screening period; Positive urine drug abuse test during screening period;
- Habitually drinking grapefruit juice or excessive amounts of tea, coffee, and/or caffeinated beverages, and unable to quit during the study period;
- Engaged in working that require long-term exposure to radioactive conditions; Or those who have significant radiation exposure (≥ 2 chest/abdominal CT scans, or ≥ 3 other types of X-ray examinations) or participated in radiopharmaceutical labeling tests within 1 year before the study;
- Those who have received vaccines within 1 month before screening or have vaccination plans during the study;
- Individuals with a history of needle or blood fainting and have difficulty or cannot tolerate venous puncture for blood collection;
- Those who have fertility plans during the study period and within 1 year after the completion of the study; or those who do not agree to adopt strict contraceptive measures during the experiment and within 1 year after the completion of the study;
- Individuals who have experienced blood loss or donated up to 400 mL of blood within 3 months prior to the screening period, or have received blood transfusions, or plan to donate blood within 1 month after the end of this study;
- Subjects that are not suitable for participating in this study due to other factors as judged by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: [14C] TQB3616
100 µCi [14C] TQB3616, 180mg, once in total.
|
TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak concentration (Cmax)
Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
Maximum plasma drug concentration
|
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
|
Area under drug time curve
Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
Area under the blood concentration time curve
|
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
|
Time to peak concentration (Tmax)
Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
Time to reach maximum (peak) plasma concentration following drug administration
|
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
|
Elimination half-life (t1/2)
Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
The time it takes for the blood concentration of a drug to decrease from its highest value to half in the body.
|
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
|
Mean resident time (MRT)
Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
The average time that drug molecules remain in the body.
|
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 336 hours after dose.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse event rate
Time Frame: Baseline up to 21 days after administration
|
The incidence of adverse events after administration.
|
Baseline up to 21 days after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TQB3616-I-04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.